- Home
- PZZA vs CVAC Comparison
PZZA vs CVAC Comparison
Compare PZZA & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- CVAC
- Stock Information
- Founded
- PZZA 1984
- CVAC 2000
- Country
- PZZA United States
- CVAC Germany
- Employees
- PZZA N/A
- CVAC N/A
- Industry
- PZZA Restaurants
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- CVAC Health Care
- Exchange
- PZZA Nasdaq
- CVAC Nasdaq
- Market Cap
- PZZA 1.4B
- CVAC 1.2B
- IPO Year
- PZZA 1993
- CVAC 2020
- Fundamental
- Price
- PZZA $48.64
- CVAC $5.38
- Analyst Decision
- PZZA Buy
- CVAC Hold
- Analyst Count
- PZZA 10
- CVAC 3
- Target Price
- PZZA $52.33
- CVAC $6.83
- AVG Volume (30 Days)
- PZZA 1.2M
- CVAC 636.4K
- Earning Date
- PZZA 08-07-2025
- CVAC 08-15-2025
- Dividend Yield
- PZZA 3.78%
- CVAC N/A
- EPS Growth
- PZZA 8.47
- CVAC N/A
- EPS
- PZZA 2.28
- CVAC 1.01
- Revenue
- PZZA $2,085,052,000.00
- CVAC $599,540,810.00
- Revenue This Year
- PZZA $4.40
- CVAC N/A
- Revenue Next Year
- PZZA $0.98
- CVAC $24.04
- P/E Ratio
- PZZA $21.38
- CVAC $5.34
- Revenue Growth
- PZZA N/A
- CVAC 675.15
- 52 Week Low
- PZZA $30.16
- CVAC $2.37
- 52 Week High
- PZZA $60.75
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- PZZA 62.29
- CVAC 46.15
- Support Level
- PZZA $43.94
- CVAC $5.36
- Resistance Level
- PZZA $49.91
- CVAC $5.48
- Average True Range (ATR)
- PZZA 1.78
- CVAC 0.05
- MACD
- PZZA 0.48
- CVAC -0.02
- Stochastic Oscillator
- PZZA 84.05
- CVAC 11.11
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.